The preparation Proctyl is used in situations involving certain distressing symptoms in the anorectal area. It is commonly used across conditions presenting with acute episodes where symptoms may intensify temporarily, including the management of symptoms associated with hemorrhoids, anal fissures, and localized anorectal inflammation.

Relief of Pain, Itching, and Burning Sensations

This preparation is generally applied to help address symptom clusters related to physical discomfort and sensory distress, such as localized pain, intense itching (pruritus), and a persistent burning sensation. It is relevant for managing symptoms that interfere with daily comfort. The medication helps ease the overall symptom load during episodes of sensory discomfort.

Supportive Management of Tissue Irritation and Bleeding

The medication is considered relevant in conditions involving inflammatory or irritative states where the patient experiences physical manifestations like localized inflammation, swelling, or minor capillary bleeding. It plays a role in managing symptoms that create noticeable physiological strain. This application supports patients during difficult episodes by easing distress.

“The medication helps ease the overall symptom load and supports general well-being during symptomatic periods.”

---

Quick Fact: Supportive Symptom Management

---

This usage assists with maintaining functional stability when symptoms become more noticeable and contributes to easing the overall symptom load during these difficult episodes.

Regulatory References

1. The National Agency of Drug and Food Control of Indonesia (BPOM)

Population Eligibility Rules for Proctyl

Proctyl, a combination product containing Cinchocaine and Policresulen, has specific eligibility rules and restrictions defined in regulatory documents. Eligibility is established for the adult population (18 years and older) under standard labeled conditions for topical use.

Absolute Contraindications

The medicine is officially contraindicated and must not be used by patients with a known hypersensitivity (allergy) to cinchocaine, policresulen, or any other component of the formulation. Use is also contraindicated in patients with an existing systemic infection and is prohibited in infants and young children, generally those under two years of age.

Age-Related and Conditional Use

Population Group	Regulatory Status
Children under 12 years	Use not established; insufficient safety data is available.
Adolescents (12–18 years)	Not recommended due to lack of comprehensive safety data.
Pregnancy	Conditional use; restricted and requires a medical benefit-risk assessment.
Lactation (Breastfeeding)	Conditional use; use requires medical caution and evaluation.

Regulatory documents define a clear structure for use: absolute prohibitions prevent use in specific non-eligible groups, while for pregnant and breastfeeding individuals, use is conditional upon a professional assessment of benefits versus potential risks.

The official regulatory profile for the Proctyl combination product identifies interaction patterns based on both the systemic potential of the Cinchocaine component and the localized action of the Policresulen component.

Pharmacokinetic Interactions with Systemic Medicines

Certain systemic medicinal products are documented to pose a risk of a pharmacokinetic interaction. This primarily involves co-administration with strong metabolic inhibitors, specifically the anti-retrovirals Ritonavir and Cobicistat. These agents can inhibit the metabolism of the Cinchocaine component, which carries a risk of increased systemic exposure and plasma concentrations. This interaction pattern is classified as a combination requiring caution under regulatory guidelines, with the formal outcome being the heightened potential for systemic side effects due to altered drug levels.

Local Administration Restrictions and Pharmacodynamic Interference

The Policresulen component introduces specific restrictions concerning local co-administration. To avoid chemical incompatibility or potential reduction in efficacy, regulatory documentation advises against the simultaneous topical use of other agents or treatments at the application site. This includes preparations, such as certain antiseptics or disinfectants, that are known to alter the pH of the mucous membranes. Due to the risk of local interference, the label establishes a timing rule, advising against the co-administration of more than one drug at the same site at the same time. This constitutes a mandatory local co-administration restriction.

How Proctyl Works

Local Sodium Channel Inhibition

The cinchocaine hydrochloride component acts at the local sensory nerves by stabilizing the neuronal membrane. It engages with mechanisms that block the initiation and conduction of nerve impulses by decreasing the membrane's permeability to sodium ions (Na^+) through voltage-gated sodium channel inhibition. This action modifies early molecular steps, resulting in the local abolition of sensory signal propagation at the nerve terminal.

Tissue Denaturation and Pathway Modulation

The policresulen component engages mechanisms that regulate protein interaction within the targeted tissue. It acts by causing selective protein denaturation and subsequent tissue coagulation of pathologically altered cells. This physicochemical action triggers localized vasoconstriction and induction of capillary thrombosis within small vessels, modifying early molecular steps that result in hemostasis. Furthermore, policresulen exerts protein-binding activity on the tissue surface, which modifies local fluid flux and results in decreased secretion of inflammatory mediators, while simultaneously modulating systems to induce proliferation and migration of epithelial cells for tissue restoration.

How to Use Proctyl: Administration Guidelines

Proctyl, a combination product containing Cinchocaine and Policresulen, is formulated exclusively for local application and follows a specific protocol for administration. The medication is supplied in two primary forms: a rectal ointment and a suppository, which define the methods of use.

---

Administration and Dosage Frequency

The preparation is administered via the topical or intrarectal route. The standard adult dosing regimen involves applying a small amount of the ointment to the affected anorectal area, or inserting one suppository unit per dose. This regimen is typically carried out at a frequency of two to three times daily to maintain continuous localized action.

For internal application of the rectal ointment, the use of the specific applicator supplied with the product is procedurally necessary. To ensure maximum retention and contact time with the localized tissue, administration is generally performed following a bowel movement.

---

Duration and Use Constraints

Proctyl is intended for short-term symptomatic management. The duration of use is typically limited, and treatment should be reviewed by a professional if symptoms fail to improve or persist after approximately seven days. There are no explicit, formulaic dose adjustments provided for older adults or patients with organ impairment; therefore, use outside of the general regimen remains dependent on professional direction.

---

Usage Entity	General Standard
Route of Administration	Topical / Intrarectal
Frequency Pattern	Multiple times daily (2–3 times)
Use-Context Constraint	Short-term; Consult professional if symptoms persist beyond 7 days

Research Evidence / Overview of Studies for Proctyl (Cinchocaine / Policresulen)

The research available for the Cinchocaine and Policresulen combination has been studied for several common anorectal conditions. This overview focuses strictly on the evidence landscape, including the types of research conducted, the outcomes measured, and what remains uncertain according to scientific and regulatory sources. Findings describe group patterns observed in the studies and do not provide individual predictions.

---

Evidence for Use in Symptomatic Hemorrhoids

Research exploring the symptom complex associated with hemorrhoids includes large-scale observational studies, case series, and a limited number of prospective, controlled trials. These studies primarily evaluated the preparation in adults with hemorrhoids over short-term periods, typically examining patient-reported outcomes describing perceived discomfort related to pain, itching, burning, and the status of minor bleeding. The findings describe patterns observed in the studies, providing insight into short-term symptom patterns. However, the evidence quality varies across studies, and the certainty level reflects the limitations of the available comparative research.

Research in Acute Anal Fissures and Rhagades

Research has explored short-term symptom changes in adult patients presenting with acute anal fissures. Evidence is often derived from case series or secondary data within broader multicenter studies. Outcomes measured included pain severity (using rating scales) and the observation of tissue status during research exploring short-term symptom changes. Evidence for this specific application is generally collected as secondary data, and studies focused solely on this indication often have sample sizes that were modest.

Studies on Supportive Postoperative Management

Controlled studies have evaluated the preparation in adult patients following proctologic procedures, such as hemorrhoidectomy, to monitor outcomes related to physical discomfort, primarily postoperative pain intensity. The findings were mixed regarding the measurable change in pain intensity when compared to control groups. Some controlled research data show patterns related to no observable difference in pain scores when compared to a control group, leading to low certainty for this specific application.

---

Research Gaps and Areas of Uncertainty

Evidence highlights what is known — and what is still uncertain about the combination. Long-term effects are not fully established, as the majority of studies observed responses over defined time intervals that were relatively short-term. Comparative evidence is lacking for many direct head-to-head trials against other contemporary products. Furthermore, the results apply only to the populations studied, and data for certain groups remain insufficient, particularly for children and pregnant populations.

Key Studies & References Assessment Report on Proctyl (Cinchocaine / Policresulen) - National Agency of Drug and Food Control of Indonesia (BPOM)

Common questions about Proctyl (FAQ)

Q: Is Proctyl only for hemorrhoids, or can it be used for other issues?

According to the official product information, Proctyl is indicated for use beyond just hemorrhoids. Regulatory documents state it is used for the treatment of anal fissures, anal pruritus (itching), and eczema, and as a supportive dressing following proctological surgery.

Q: How quickly can I expect to notice any effects from Proctyl?

Studies on the medication's mechanism of action indicate that it includes an active ingredient that acts as a local anesthetic, Cinchocaine. This component is intended to contribute to relief from initial pain and reduce uncomfortable itching sensations.

Q: What is the difference between Proctyl and other common products for similar issues?

The compositional difference is Proctyl's dual mechanism of action, as described in official documents. One component, Policresulen, engages a mechanism of coagulation (sealing of damaged tissue) and hemostasis. The other component, Cinchocaine, provides local anesthetic relief from pain and itching, offering a two-pronged approach.

Q: Can Proctyl cause sleepiness or affect my ability to drive?

Official safety advice indicates that Proctyl is unlikely to affect the ability to drive or operate machinery. However, regulatory documents advise caution, noting that if side effects impair concentration, activities requiring alertness should be avoided.

Q: Is it normal to feel a slight burning or itching sensation when first using Proctyl?

Official documentation describes mild local discomforts such as burning or itching may occasionally be noted when starting treatment. This sensation is known to be associated with the active substance, and in most cases, it subsides rapidly.

Q: Can using Proctyl for a long time make the problem worse?

Official guidance establishes a short-term use context, advising that treatment should be reviewed by a professional if symptoms fail to improve or persist after approximately seven days. The product information does not support use beyond this defined period without professional review.

Q: What is the general safety classification of Proctyl?

For certain populations, such as during pregnancy, the safety of the combination product is not fully established. Official information describes use as being restricted and conditional upon a medical benefit-risk assessment.

Q: Can Proctyl cause skin discoloration or changes where it is applied?

Uncommon undesirable effects that have been reported include localized skin changes. These include inflammatory reddening (erythema), mild skin rashes, or the formation of small fluid-filled bumps (vesicles) at the application site.

Q: Does Proctyl have any known effects on the liver or kidneys?

The local anesthetic component, Cinchocaine, is metabolized (processed) by the liver. Due to the medication's topical nature, official documentation indicates systemic exposure is typically low with topical administration.

Q: What is the role of the ingredients besides the main active one?

The ingredients besides the active components (called excipients) can sometimes carry safety warnings. Official documents mention the presence of substances like phospholipids derived from soya beans. Because of this, the medication is contraindicated for individuals with a known hypersensitivity to soya or peanuts.

Q: What should be done if I experience an unexpected effect after using Proctyl?

In the very rare event that a person experiences signs of a severe systemic allergic reaction, such as swelling of the throat or difficulty breathing (anaphylaxis), regulatory guidelines note that treatment is to be discontinued immediately, and medical assistance should be sought.

Q: Does Proctyl have any systemic absorption?

Official pharmacokinetic information indicates that the local anesthetic component, Cinchocaine, can be absorbed across the mucous membranes, though absorption through intact skin is minimal. The other component, Policresulen, is an organic acid with a high molecular weight.

Q: Are there any religious or dietary restrictions related to the ingredients of Proctyl?

Official information includes a safety warning for certain excipients. The product is contraindicated for people with known allergies to soya or peanuts due to the presence of phospholipids from soya beans in the base of the product.

Q: Is Proctyl considered a steroid or does it contain a steroid?

The formulation is based on a combination of Policresulen and Cinchocaine. Clinical studies referenced in regulatory documents confirm that this combination is used without the addition of corticosteroids (steroids) or antibiotics.

Q: Is there any evidence about Proctyl's use in elderly patients?

The Summary of Product Characteristics, which details official prescribing information, provides a standard adult dosage for use. The documents do not specify a particular dose adjustment or separate regimen for older patients.

How to Store and Dispose of Proctyl?

Official regulatory guidelines establish mandatory storage conditions that differ based on the product form:

• Ointment: Must be stored below 25 C in a cool, dry, and dark environment.
• Suppositories: Require refrigeration, with temperatures maintained between 2 C and 8 C. Freezing is strictly prohibited.

All forms must be kept out of the reach and sight of children to prevent accidental access. To maintain product stability, the medicine should not be used past the expiration date printed on the packaging.

Regarding disposal, regulatory documents prohibit discarding unused or expired Proctyl in household waste or flushing it down a toilet or sink. The product must be returned to a pharmacist for proper pharmaceutical waste handling and environmentally safe disposal.